Ars Technica
3 months agoBiogen dumps dubious Alzheimer's drug after profit-killing FDA scandal
Biogen is abandoning its Alzheimer's drug Aduhelm and terminating all development and commercialization activities.
The drug failed two Phase 3 trials and has faced controversy over its regulatory approval and pricing. [ more ]